The risk of bipolar disorders and major depressive disorders in Wilson’s disease

Carta, Maria; Gp, Farina; Sorbello, Orazio; Moro, Maria Francesca; Cadoni, Federica; Serra, Alessandra; Mura, Gioia; Piga, M.; Demelia, Enrico

doi:10.1097/01.yic.0000423352.61450.57

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[43] The prevalence of depression in patients with WD varies broadly (4%-47%) depending on the assessment instrument. [45,46] The mechanisms of depression in WD appear similar to those in MDD, namely, alteration of serotoninergic transmission in the thalamus-hypothalamus and midbrain-pons region, notably with low density of the presynaptic serotonin transporter. [47] In contrast, dysthymic disorder (dysthymia) is a chronic depressive disorder of at least 2 years' duration in adults, differing slightly from MDD clinically.…”

Section: Depressive Disordersmentioning

confidence: 99%

See 1 more Smart Citation

A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases

et al. 2022

View full text Add to dashboard Cite

This is the complete version of the American Association for the Study of Liver Diseases (AASLD) 2022 Guidance on Wilson disease (WD). It provides a contemporary approach to diagnosis and management of WD. Guidance documents, developed by a panel of experts, are formulated as recommendations to help clinicians implement the most current strategies for diagnosis and management. This Guidance was developed with the support and oversight of the AASLD Practice Guidelines Committee. The AASLD Practice Guidelines Committee chose to commission a guidance, rather than a guideline, because of the paucity of randomized controlled trials on this topic. AASLD Guidelines are supported by systematic reviews of the literature, formal ratings of evidence quality and strength of recommendations, and, if appropriate, meta-analysis of results using the Grading of Recommendations Assessment Development and Evaluation system. In contrast, this narrative review and its guidance statements are based on (1) formal review and analysis of the recently published international literature on WD, (2) guideline policies of the AASLD, and (3) the authors' experience. This practice Guidance is intended for use by physicians and other health professionals. As clinically appropriate, guidance statements should be tailored to the needs of individual patients. Specific guidance statements are evidence based whenever possible. Where such evidence is unavailable or inconsistent, guidance statements are based on expert consensus opinion. An executive summary providing a convenient overview is available (

show abstract

Section: Depressive Disordersmentioning

confidence: 99%

“…[48] Patients with WD may present with various degrees of mood instability that do not meet criteria for mania or hypomania but nevertheless impair quality of life. [46,49]…”

Section: Bipolar Disorders/bipolar Spectrummentioning

confidence: 99%